Induction of anti-VEGF therapy resistance by upregulated expression of microseminoprotein (MSMP)

T. Mitamura, S. Pradeep, M. McGuire, S. Y. Wu, S. Ma, H. Hatakeyama, Y. A. Lyons, T. Hisamatsu, K. Noh, A. Villar-Prados, X. Chen, C. Ivan, C. Rodriguez-Aguayo, W. Hu, G. Lopez-Berestein, R. L. Coleman, A. K. Sood

Research output: Contribution to journalArticlepeer-review

32 Scopus citations

Abstract

Anti-vascular endothelial growth factor (VEGF) therapy has demonstrated efficacy in treating human metastatic cancers, but therapeutic resistance is a practical limitation and most tumors eventually become unresponsive. To identify microenvironmental factors underlying the resistance of cancer to antiangiogenesis therapy, we conducted genomic analyses of intraperitoneal ovarian tumors in which adaptive resistance to anti-VEGF therapy (B20 antibody) developed. We found that expression of the microseminoprotein, prostate-associated (MSMP) gene was substantially upregulated in resistant compared with control tumors. MSMP secretion from cancer cells was induced by hypoxia, triggering MAPK signaling in endothelial cells to promote tube formation in vitro. Recruitment of the transcriptional repressor CCCTC-binding factor (CTCF) to the MSMP enhancer region was decreased by histone acetylation under hypoxic conditions in cancer cells. MSMP siRNA, delivered in vivo using the DOPC nanoliposomes, restored tumor sensitivity to anti-VEGF therapy. In ovarian cancer patients treated with bevacizumab, serum MSMP concentration increased significantly only in non-responders. These findings imply that MSMP inhibition combined with the use of antiangiogenesis drugs may be a new strategy to overcome resistance to antiangiogenesis therapy.

Original languageEnglish (US)
Pages (from-to)722-731
Number of pages10
JournalOncogene
Volume37
Issue number6
DOIs
StatePublished - Feb 8 2018
Externally publishedYes

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Cancer Research

Fingerprint

Dive into the research topics of 'Induction of anti-VEGF therapy resistance by upregulated expression of microseminoprotein (MSMP)'. Together they form a unique fingerprint.

Cite this